A. Anelli a, E. Sbidian b, J.-F. Huon c, S. Valyi d, S. Barbarot a, M. Beylot-Barry e, C. Girard f, D. Jullien g, h, C. Paul i, H. Aubert a, ⁎ 
on behalf of the French Psoriasis Research Group (GrPSO) of the French Society of Dermatology
a Department of Dermatology, CHU Nantes and INSERM CIC 004, 44000 Nantes, France
b Department of Dermatology, Assistance Publique- Hôpitaux de Paris, Hôpital Saint-Louis, Université Paris Cité, Paris, France
c Department of Pharmacology, CHU Nantes 44000 Nantes France
d Department of National Health, CHU Nantes 44000 Nantes France
e Department of Dermatology, CHU de Bordeaux, INSERM 1312, Université Bordeaux, Bordeaux, France
f Department of Dermatology, CHU de Montpellier, Montpellier, France
g Department of Dermatology, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon F-69003, France
h Lyon-1 University, INSERM U1111 - CIRI, Lyon F-69007, France
i Department of Dermatology-Allergology, Toulouse University and CHU de Toulouse-Larrey, Toulouse, France